Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of LGK974 alone and with PDR001 in Wnt ligand-dependent malignancies
NL-OMON55368Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2011
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of WNT974 and spartalizumab in colorectal cancer (CRC), pancreatic adenocarcinoma (PDAC), triple-negative breast cancer (TNBC) and 6 more (4 arms), sponsored by Novartis. Primary endpoint: Dose-limiting toxicities. Started Dec 2011; status: active, not recruiting.
02
Drugs
WNT974spartalizumab
03
Conditions
colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)triple-negative breast cancer (TNBC)melanomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON55368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55368.